Credit Suisse Sees Solid Q4 Earnings For Kite Pharma By: Benzinga via Benzinga March 27, 2015 at 09:03 AM EDT In a report published Friday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating and $79.00 price target on Kite ... Read More >>